UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51481 STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its charter) | Delaware | 13-3986004 | | --- | --- | | (State or Other Jurisdiction of incorporatio ...

STRATA Skin Sciences (SSKN) Q2 2025 Earnings Call August 13, 2025 04:30 PM ET Speaker0Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the Strata Skin Sciences Inc. Second Quarter twenty twenty five Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen only mode. Participants of this call are advised that the audio of this conference call is being broadcast live over the Internet and is also being recorded for playback purposes. ...

Exhibit 99.1 STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Gross profit for the second quarter of 2025 was $4.3 million, or 56% of revenue, down from $5.0 million in the second quarter of 2024. Total operating expenses were $6.5 million in the second quarter of 2025 vs. $5.5 million in the prior-year period. Net loss for the second quarter of 2025 was $2.5 million, or EPS of negative $0.60 per basic and diluted common share, as compared to a net loss of $ ...

HORSHAM, Penn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended June 30, 2025, and provides a corporate update. Second Quarter Highlights Historic expansion of CPT codes for reimbursement for inflammatory and auto-immune skin diseases, effectively tr ...

Core Insights - STRATA Skin Sciences is working with CMS to obtain temporary codes for expanded reimbursement of its XTRAC excimer laser treatment, aiming for implementation as early as the 2026 rule cycle [2][3] - The American Medical Association has approved updates to CPT codes, expanding reimbursement eligibility for XTRAC treatments to include various inflammatory and autoimmune skin conditions effective January 1, 2027 [2] - STRATA's efforts could potentially triple the addressable patient population, benefiting over 30 million individuals with chronic skin conditions [3] Company Developments - STRATA has received significant support from legislators, patient advocacy groups, and academic leaders, reinforcing confidence in the efficacy of Excimer Laser therapy [4] - Recent peer-reviewed studies have confirmed the safety and effectiveness of combining 308-nm excimer laser therapy with JAK inhibitors for treating vitiligo, with one study showing a 100% overall response rate [5][6] - The company is involved in ongoing litigation against LaserOptek America, with the Federal District Court agreeing to add LaserOptek Korea as a defendant, indicating potential for significant damages [7][8] Product and Market Strategy - STRATA's XTRAC excimer laser is positioned as a leading drug-free option for treating skin conditions, with a focus on enhancing patient outcomes [4][9] - The company offers a unique Partnership Program that includes a fee per treatment cost structure, on-site training, and marketing support to promote its technologies [11] - STRATA's intellectual property portfolio includes patents for localized treatment methods, positioning the company for future growth in the dermatology market [9]

HORSHAM, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report second quarter 2025 financial results on Wednesday, August 13, 2025 after the market close. STRATA management will subsequently host a conference call at 4:30 p.m. ET on Wednesday, August 13, 2025 to review finan ...

Driving Value in Dermatology Matching Patients with Clinics for a Win-Win-Win Outcome Investor Presentation December 2024 NASDAQ: SSKN Safe Harbor Statement This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements of the plans, strat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF Registrant's telephone number, including area code: (215) 619-3200 Securities registered pursuant to Section 12(b) of the Act: | | | Name Of Each Exchange On Which | | --- | --- | --- | | Title of Each Cl ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $6.8 million, up 1% compared to Q1 2024 [15] - Global recurring revenue for Q1 2025 was $4.7 million, also up 1% year-over-year [15] - Gross profit increased to $3.6 million for Q1 2025, up from $3.1 million in the same period in 2024, resulting in a gross margin of 53.5% compared to 45.6% in Q1 2024 [16] - Total operating expenses decreased to $5.7 million in Q1 2025 from $6.0 million in Q1 2024, a reduction of 5% [16] - Cash burn improved to $749,000 in Q1 2025 from $1.55 million in the prior year [17] Business Line Data and Key Metrics Changes - The installed base of XTRAC devices in the U.S. is approximately 850, with a significant increase in recurring revenue per device [5][9] - The TheraClear X device installed base reached 160 units, up from 104 units at the end of Q1 2024, with revenue growing over 50% year-over-year in six of the last seven quarters [11] - The number of patients submitted for reimbursement for TheraClear X increased by 138% year-over-year, with pre-authorization rates exceeding 85% [12][26] Market Data and Key Metrics Changes - International business sales reached $2.5 million, up 8% year-over-year, with equipment sales up 13% and recurring treatments revenue up 27% [12] - The company is cautiously monitoring the potential negative impact of tariffs on near-term sales, particularly in international markets [13][19] Company Strategy and Development Direction - The company is executing a multifaceted turnaround strategy focused on increasing recurring revenue per device and optimizing device placements [4][5] - The Elevate360 consulting model is being expanded to improve patient conversion and device utilization in underperforming clinics [6][7] - The strategy includes removing underutilized devices to ensure capital efficiency and focusing on clinics that show potential for growth [7][49] Management's Comments on Operating Environment and Future Outlook - Management expressed caution regarding the potential impact of tariffs on international revenue, although there was no immediate effect observed in Q1 2025 [18][19] - The company anticipates favorable outcomes from ongoing discussions regarding reimbursement coverage expansions [10] - Management is optimistic about the traction gained from the turnaround strategy and the increasing demand for cost-effective treatments [12] Other Important Information - The average revenue per XTRAC device in the U.S. was approximately $22,000 in 2024, with potential for significant revenue growth from existing devices [8][9] - The company exited Q1 2025 with cash and cash equivalents totaling $7.8 million, including $1.3 million of restricted cash [18] Q&A Session Summary Question: Can you discuss the TheraClear pipeline and marketplace learnings? - Management noted that the installed base is growing, with 160 devices deployed and a significant increase in patients submitted for reimbursement [21][22] Question: What are the utilization trends for TheraClear? - Management provided insights on the revenue breakeven points and the expected number of procedures per device, indicating a strong potential for growth [28][29] Question: Is there any potential impact from tariffs on domestic business? - Management clarified that the domestic supply chain is minimally impacted by tariffs, primarily affecting international sales and service support [36][38] Question: What is the focus for the rest of 2025 regarding the installed base? - Management indicated a dual focus on increasing utilization of the current installed base while also seeking to sign new clinics [40][41]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $6.8 million, up 1% compared to Q1 2024 [16] - Global recurring revenue for Q1 2025 was $4.7 million, also up 1% year-over-year [16] - Gross profit increased to $3.6 million for Q1 2025, up from $3.1 million in the same period in 2024, resulting in a gross margin of 53.5% compared to 45.6% in Q1 2024 [17] - Total operating expenses decreased to $5.7 million in Q1 2025 from $6.0 million in Q1 2024, a reduction of 5% [18] - Cash burn improved to $749,000 in Q1 2025 from $1.55 million in the prior year [19] Business Line Data and Key Metrics Changes - The installed base of XTRAC devices in the U.S. is approximately 850, with a significant increase in recurring revenue per device [6][11] - The TheraClear X device installed base reached 160 units, up from 104 units at the end of Q1 2024, with revenue growing over 50% year-over-year in six of the last seven quarters [13] - The number of patients submitted for reimbursement for TheraClear X increased by 138% year-over-year, with pre-authorization rates exceeding 85% [14][29] Market Data and Key Metrics Changes - International business sales reached $2.5 million, up 8% year-over-year, with equipment sales up 13% and recurring treatments revenue up 27% [14] - The company is cautiously monitoring the potential negative impact of tariffs on international sales, particularly in Asian markets [15][41] Company Strategy and Development Direction - The company is executing a multifaceted turnaround strategy focused on increasing recurring revenue per device and optimizing device placements [5] - The Elevate360 consulting model is being expanded to improve patient conversion and device utilization in underperforming clinics [6][7] - The strategy includes removing underutilized devices to ensure capital efficiency and focusing on clinics that show potential for growth [9][54] Management's Comments on Operating Environment and Future Outlook - Management cautioned about potential impacts of tariffs on international business, although there was no immediate effect observed in Q1 2025 [20] - The company anticipates favorable outcomes from ongoing discussions regarding reimbursement coverage expansions [12] - Management expressed optimism about the traction gained from the turnaround strategy and the increase in demand for cost-effective treatments [14] Other Important Information - The company exited Q1 2025 with cash and cash equivalents totaling $7.8 million, including $1.3 million of restricted cash [20] - The average revenue per XTRAC device in the U.S. was approximately $22,000 in 2024, indicating potential for significant revenue growth with increased utilization [10] Q&A Session Summary Question: Can you discuss the TheraClear pipeline and marketplace learnings? - Management noted that the installed base is growing, with 160 devices deployed and a significant increase in patients submitted for reimbursement [24][25] Question: What are the utilization trends for TheraClear? - Management provided insights on the revenue breakeven points and the expected number of procedures per device, indicating a focus on increasing utilization [31] Question: What is the potential impact of tariffs on domestic business? - Management clarified that the domestic supply chain is minimally impacted by tariffs, but there are peripheral effects due to suppliers raising prices [41][42] Question: What is the focus for the rest of 2025 regarding the installed base? - Management indicated a dual focus on increasing utilization of the current installed base while also signing new clinics [46][54] Question: How many clinics could benefit from the Elevate360 program? - Management stated that they are currently implementing the program in about 100 accounts, with plans for further expansion [58][60]